Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | LDHA | P00338 | 2/20 | 0.36 |
| ▸ | LDHB | P07195 | 2/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30715778 | 0.86 | HTT (0.52) | HRH3KDM4EALDH1A1NOS2HTR1D | |
| SCHEMBL27995904 | 0.85 | HRH3 (0.54) | HRH3KDM4EALDH1A1HTR1DMAPK1 | |
| SCHEMBL28349815 | 0.84 | PTGS2 (0.46) | HRH3NOS2HPGDNPC1MAPK1 | |
| SCHEMBL2046505 | 0.84 | HTT (0.50) | HRH3KDM4EALDH1A1HPGDNPC1 | |
| SCHEMBL19446551 | 0.84 | HRH3 (0.37) | HRH3KDM4EALDH1A1NOS2NOS3 | |
| SCHEMBL8733028 | 0.82 | PTGS2 (0.48) | HRH3HPGDNPC1MAPK1HTT | |
| SCHEMBL2456019 | 0.82 | PTGS2 (0.48) | HRH3HPGDNPC1MAPK1HTT | |
| SCHEMBL2452906 | 0.82 | PTGS2 (0.48) | HRH3HPGDNPC1MAPK1HTT | |
| SCHEMBL1988145 | 0.82 | PTGS2 (0.48) | HRH3HPGDNPC1MAPK1HTT | |
| Ammonia Solution, Strong SCHEMBL3636757 | 0.82 | ALDH1A1 (0.43) | HRH3KDM4EALDH1A1NOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108949262-A | A kind of diesel energy-saving power type detersive and preparation method thereof | 滨州仁泰化工有限公司 | 2018-12-07 | — | — | CN | claimed |
| CN-114133398-B | Amino acid substituted acyclovir tricyclic nucleoside derivative and synthesis method and application thereof | 中南民族大学 | 2022-11-22 | — | — | CN | disclosed |
| EP-2590973-B1 | SOLIFENACIN SALTS | CRYSTAL PHARMA SAU (ES) | 2016-08-31 | — | — | EP | disclosed |
| US-8765785-B2 | Solifenacin salts | CRYSTAL PHARMA, S.A.U. (ES) | 2014-07-01 | — | — | US | disclosed |
| US-20130203804-A1 | SOLIFENACIN SALTS | CRYSTAL PHARMA, S.A.U. (ES) | 2013-08-08 | — | — | US | disclosed |
| EP-2590973-A1 | SOLIFENACIN SALTS | Crystal Pharma S.A.U (ES) | 2013-05-15 | — | — | EP | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2012079583-A1 | SYSTEM PROVIDING CONTROLLED DELIVERY OF GASEOUS CO FOR CARBONYLATION REACTIONS | AARHUS UNIVERSITET (DK) | 2012-06-21 | — | — | WO | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| WO-2012004264-A1 | SOLIFENACIN SALTS | RAGACTIVES, S.L.U. (ES) | 2012-01-12 | — | — | WO | disclosed |
| EP-1569652-A2 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | Pharmasset Ltd. (BB) | 2005-09-07 | — | — | EP | disclosed |
| US-6908924-B2 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | PHARMASSET, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | GILEAD PHARMASSET LLC | 2004-10-28 | — | — | US | disclosed |
| EP-1461041-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | Pharmasset Ltd. (BB) | 2004-09-29 | — | — | EP | disclosed |
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | GILEAD PHARMASSET LLC | 2003-09-18 | — | — | US | disclosed |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | PHARMASSET, INC. | 2003-08-28 | — | — | US | disclosed |
| WO-2003063771-A2 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET LTD. (BB) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003051298-A2 | PREPARATION OF INTERMEDIATES USEFUL IN THE SYNTHESIS OF ANTIVIRAL NUCLEOSIDES | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051306-A2 | N4-ACYLCYTOSINE-1,3-DIOXOLANE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET LTD. (BB) | 2003-06-26 | — | — | WO | disclosed |
| US-4213967-A | Pesticide containing ignition inhibitor | DR. WERNER FREYBERG, CHEMISCHE FABRIK DELITIA NACHF. (DE) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176319-A1 | For therapy and prophylaxis of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections, in human patients or other animal hosts | ENTPD5, CDA, ADA | HRH3 983/4885KDM4E 1678/4885ALDH1A1 645/4885 |
| US-20040214844-A1 | N4-acylcytosine nucleosides for treatment of viral infections | ENTPD5, DUT, PNP | HRH3 1160/4885KDM4E 1112/4885ALDH1A1 2002/4885 |
| US-20030162992-A1 | Reacting a 2,2-dialkoxyethyl halide with an appropriate carboxylate compound to obtain acetal compound; hydrolyzing the acetal to form the alpha -acyloxyacetaldehyde | DERA, DPYD, DHPS | HRH3 2387/4885KDM4E 1415/4885ALDH1A1 14/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | HRH3 889/4885KDM4E 949/4885ALDH1A1 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.